Walgreens Boots Alliance — Q1 2020 Earnings Presentation
26 slides from Walgreens Boots Alliance's earnings presentation, Jan 8, 2020
Slide 1: Fiscal 2020 First Quarter Results
Fiscal 2020 First Quarter Results January 8, 2020
Slide 2: Safe harbor and non-GAAP
Safe harbor and non-GAAP Cautionary Note Regarding Forward-Looking Statements: All statements in these materials and the related presentation that are not historical including, without limitation, estimates of and goals for future tax, financial and operating performance and results and our fiscal y
Slide 3: Overview
Overview • Soft start to the year but full year guidance maintained • Making progress against four strategic priorities − Accelerate digitalization of company − Transform and restructure retail offering − Create neighbourhood health destinations around a modern pharmacy − Transformational Cost Manag
Slide 4: 1Q financial highlights
1Q financial highlights • Adjusted EPS $1.37, -5.7% lower than prior year in constant currency • RPU strong cost management and improving retail comparable sales trends offset by lower gross margin • Retail Pharmacy International impacted by challenging UK market • Pharmaceutical Wholesale delivered
Slide 5: 1Q financial highlights
1Q financial highlights Reported currency Constant currency 1Q20 Δ vs. 1Q19 Δ vs. 1Q19 $ in millions (except EPS and % change) Sales $34,339 + 1.6% + 2.3% Operating income: GAAP $1,013 - 27.6% Adjusted $1,463 - 15.6% - 15.4% Net earnings: GAAP $845 - 24.8% Adjusted $1,222 - 11.8% - 11.6% EPS: GAAP $
Slide 6: Retail Pharmacy USA – financials
Retail Pharmacy USA – financials $ in millions (except %) 1Q20 Δ vs. 1Q19 Sales $26,133 +1.6% Adj. gross profit $5,753 - 4.9% Adj. SG&A % of sales 17.6% 0.6%p Adj. operating margin 4.4% - 0.9%p Adj. operating income $1,155 - 16.2% © 2020 Walgreens Boots Alliance, Inc. All rights reserved. Refer to s
Slide 7: Retail Pharmacy USA – pharmacy
Retail Pharmacy USA – pharmacy 1Q 1Q 1Q20 vs. 1Q19 Total Comparable Pharmacy sales + 2.9% + 2.5% Prescriptions + 1.4% + 2.8% • Continued comparable prescription growth • 1Q market share 20.9%: down 55 bps including impact from store optimization • 1Q adj. gross margin declined − 50 bps specialty imp
Slide 8: Retail Pharmacy USA – retail
Retail Pharmacy USA – retail 1Q20 vs. 1Q19 1Q Total retail sales - 2.2% Comp. retail sales - 0.5% • 1Q comparable sales improved to -0.5% − ex-tobacco and e-cigarettes up +0.8% − solid comparable growth in our core Health & Wellness and Beauty categories − results aided by favorable cough/cold flu s
Slide 9: Retail Pharmacy International – financials
Retail Pharmacy International – financials Constant currency $ in millions (except %) 1Q20 Δ vs. 1Q19 Sales $2,745 - 2.7% Adj. operating margin 2.9% - 1.7%p Adj. operating income $79 - 39.1% Boots UK comp. pharmacy sales + 0.9% Boots UK comp. retail sales - 2.9% • Holding share in a declining UK ret
Slide 10: Pharmaceutical Wholesale – financials
Pharmaceutical Wholesale – financials Constant currency $ in millions (except %) 1Q20 Δ vs. 1Q19 Sales $6,007 + 8.3% Adj. operating margin 2.3% - 0.2%p Adj. operating income $229 + 4.9% • Continued strong sales growth, led by emerging markets and the UK • Adj. Op. Inc. reflects strong revenue perfor
Slide 11: Cash flow
Cash flow $ in millions 1Q20 Δ vs. 1Q19 Operating cash flow $1,061 $601 Cash capital expenditure - $387 $83 Free cash flow $674 $684 • Strong free cash flow performance driven by working capital • Key initiatives on track − inventory optimization − supplier payment terms • Strong pipeline of future
Slide 12: Transformational Cost Management Program
Transformational Cost Management Program On target to deliver in excess of $1.8 billion in annual cost savings by FY22 • Pipeline of identified initiatives leads to higher level of confidence • Savings initiatives gaining momentum • Early working capital benefits materializing, future opportunities
Slide 13: Transformational Cost Management Program
Transformational Cost Management Program On target to deliver in excess of $1.8 billion in annual cost savings by FY22 Smart • Accelerating energy management efficiency program • Assessing GPO for goods not for resale Spend • Rolling out policies aligned to best in class standards • End-to-end proce
Slide 14: Retail Pharmacy USA – initiatives
Retail Pharmacy USA – initiatives • Kroger relationship takes another step forward: Transform and - pilot stores experiencing strong sales lift restructure retail - Retail Procurement Alliance unlocks future efficiencies offering • Solid performance in core categories Health & Wellness and Beauty •
Slide 15: Retail Pharmacy International – initiatives
Retail Pharmacy International – initiatives • 26 UK beauty halls implemented: performance in line with our expectations • Rebalanced 200 stores and introduced 20 new UK beauty brands Transform retail • Partnership with Mothercare to become exclusive UK franchisee in baby category • Agreement in Indo
Slide 16: Refer to safe harbor and non-GAAP on page 2 and endnotes on page 17
© 2020 Walgreens Boots Alliance, Inc. All rights reserved. Refer to safe harbor and non-GAAP on page 2 and endnotes on page 17 16
Slide 17: Endnotes
Endnotes • Please see appendix for reconciliations of non-GAAP financial measures and related disclosures ◦ The company presents certain information related to current period operating results in “constant currency,” which is a non-GAAP financial measure. These amounts are calculated by translating
Slide 18: Appendix
Appendix The following information provides reconciliations of the supplemental non-GAAP financial measures, as defined under SEC rules, presented in this presentation to the most directly comparable financial measures calculated and presented in accordance with generally accepted accounting princip
Slide 19: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) NET EARNINGS Three months ended November 30, Change vs. 1Q19 2019 2018 Amount Percent Net earnings attributable to Walgreens Boots Alliance, Inc. (GAAP) $
Slide 20: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) DILUTED NET EARNINGS PER SHARE Three months ended November 30, Change vs. 1Q19 2019 2018 Amount Percent Diluted net earnings per common share (GAAP) $ 0.95 $ 1.18 $ (0.2
Slide 21: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Three months ended November 30, 2019 Retail Pharmacy Retail Pharmacy Pharmaceutical Walgreens Boots USA International Wholesale1 Eliminations Alliance, Inc
Slide 22: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Three months ended November 30, 2018 Retail Pharmacy Retail Pharmacy Pharmaceutical Walgreens Boots USA International Wholesale1 Eliminations Alliance, Inc
Slide 23: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) EQUITY EARNINGS IN AMERISOURCEBERGEN Three months ended November 30, 2019 2018 Equity earnings in AmerisourceBergen (GAAP) $ 13 $ 39 U.S. tax law changes —
Slide 24: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) ADJUSTED EFFECTIVE TAX RATE Three months ended November 30, 2019 Three months ended November 30, 2018 Earnings before Earnings before income tax Income tax
Slide 25: Free cash flow
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) FREE CASH FLOW Three months ended November 30, 2019 2018 Net cash provided by operating activities (GAAP) $ 1,061 460 Less: Additions to property, plant an
Slide 26: Currency sensitivity
Currency sensitivity Exchange Rates/Impact FY19 Sep '19 Sensitivity Dec '19 Sensitivity GBP/USD 1.28 1.21 1.32 EUR/USD 1.13 1.11 1.11 TRY/USD 0.18 0.15 0.17 Fx Sales Impact vs. FY19 ~($1,800m)/~(1.3%) ~$50m/~0.0% Fx Adj. Operating Income Impact vs. FY19 ~($60m)/~(0.8%) ~$20m/~0.3% Fx Adj. EPS Impact
Walgreens Boots Alliance — Q1 2020 Earnings Presentation on 6ix